EAU 2026 – J&J strengthens its bladder hand
Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.
Regeneron has a new multiple myeloma hope
The company reveals its anti-GPRC5D T-cell engager.
A new challenger in target degradation
Ascentage hopes to become a new force in BTK.
Mid-stage promise turns to pivotal bust for Immutep
Tacti-004 is terminated for futility, and Immutep crashes 89%.
CCR8 promise and peril
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
AbbVie and RemeGen’s bispecific goes pivotal
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
Kainova bigs up EP4 antagonism
But there are no efficacy data, and the mechanism has a mountain to climb.
Corbus joins Pfizer with integrin no-go
CRB-601 and PF-06940434 fall by the wayside.
Akeso casts doubts on CD73 efforts
The company has ditched a trial of drebuxelimab plus ivonescimab.
BioNTech plans a spin-off
A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
